Abstract
A total of 544 patients was entered into a study in which 505 with small cell lung
cancer and good performances status were assessable. They were all prescribed an initial six courses of etoposide 120 mg/M2, cyclophosphamide lg/m2, methotrexate 35 mg/M2, and vincristine 1.3 mg/M2 (max 2 mg) intravenously on day 1, plus etoposide 240 mg/M2 by mouth on days 2 and 3, at 3 weekly intervals. Patients with limited disease received radiotherapy, 40 Gy in 15 fractions in 3 weeks, of the primary site between courses 2 and 3. Response rates three weeks after the second course were complete in 10% and partial in 72%. Treatment was well tolerated. At the end of the initial courses, patients in
complete or partial response (total 266) were randomised to maintenance (six more courses of the same drugs) or no maintenance chemotherapy. There was no survival advantage to either series.
cancer and good performances status were assessable. They were all prescribed an initial six courses of etoposide 120 mg/M2, cyclophosphamide lg/m2, methotrexate 35 mg/M2, and vincristine 1.3 mg/M2 (max 2 mg) intravenously on day 1, plus etoposide 240 mg/M2 by mouth on days 2 and 3, at 3 weekly intervals. Patients with limited disease received radiotherapy, 40 Gy in 15 fractions in 3 weeks, of the primary site between courses 2 and 3. Response rates three weeks after the second course were complete in 10% and partial in 72%. Treatment was well tolerated. At the end of the initial courses, patients in
complete or partial response (total 266) were randomised to maintenance (six more courses of the same drugs) or no maintenance chemotherapy. There was no survival advantage to either series.
| Original language | English |
|---|---|
| Pages (from-to) | 699 |
| Number of pages | 1 |
| Journal | Thorax |
| Volume | 40 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 1985 |
